Figure 3
From: B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma
Overall survival and progression-free survival of 94 patients with angioimmunoblastic T-cell lymphoma according to the IPI (a,b) and PIT (c,d). L, low risk (6 patients); LI, low-intermediate risk (23 patients); HI, high-intermediate risk (36 patients); H, high risk (29 patients). PIT is categorized as follows: group 1 (0 risk factor, 9 patients), group 2 (1 risk factor, 35 patients), group 3 (2 risk factors, 27 patients), and group 4 (3–4 risk factors, 11 patients).
